Hoffmann-La Roche Inc.

Other

F. Hoffmann-La Roche Ag

Brian Higgins

Kathryn Elizabeth Packman

Gwen Nichols

Fei Su

Kenneth Kolinsky

Kapil Dhingra

Richard J Lee

Brian Lestini

Kellie Glenn

Lin-Chi Chen

Kelli Glenn

There is provided a new dosage regimen for Compound A which maximizes anti-tumor activity while maintaining acceptable toxicity levels.

Method for administration

The present invention relates to a pharmaceutical product comprising a) as a first component an inhibitor of the MDM2-p53 interaction such as, for example: and b) as a second component cytarabine; as a combined preparation for the sequential or simultaneous use in the treatment of cancer.

Combination treatment for acute myeloid leukemia (AML)

A system and method for effectively communicating information using at least one mode of communication is described, in which information recipients proximate to a communications device within a pre-determined space and during a pre-determined time period are identified, from whom physiological state information is obtained that, when coupled with other characteristics information, is used to select from a plurality of information elements at least one information element to better target the information elements. The information element is then provided to the communications device so that it may be provided to the information recipients in the pre-determined space in a manner that is sensed by the information recipients.

System and method for communicating information

Treatment of proliferative diseases with a combination of a b-Raf inhibitor and MDM2 inhibitor.

Combination therapy for proliferative disorders

The present invention relates to a combination therapy of propane-1-sulfonic acid{3-[5-(4-chloro-phenyl)-1H-pyrrolo[2,3-b]pyridine-3-carbonyl-2,4-difluoro-phenyl]-amide}, or a pharmaceutically acceptable salt thereof, and an interferon for treating a patient suffering from a proliferative disorder, in particular a solid tumor, for example, colorectal cancer, melanoma, and thyroid cancer. In particular, the present invention relates to such a therapy wherein the interferon is peginterferon alfa-2a and the disorder is melanoma containing the V600E b-Raf mutation.

The present invention relates to a combination therapy of propane-1-sulfonic acid {3-[5-(4-chloro-phenyl)-1H-pyrrolo[2,3-b]pyridine-3-carbonyl]-2,4-difluoro-phenyl}-amide, or a pharmaceutically acceptable salt thereof, and an EGFR inhibitor for treating a patient suffering from a proliferative disorder, in particular a solid tumor, for example, colorectal cancer, melanoma, and thyroid cancer.

Growing community of inventors

Fresh Meadows, NY, United States of America

Brian Higgins